Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 100 citing Rosenstock: Triple therapy in type 2 diabetes. (0.08 sec) 

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

- pipex.com [PDF] 
RR Holman, KI Thorne, AJ Farmer, MJ Davies, … - New England Journal of Medicine, 2007 - content.nejm.org
From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and
Metabolism (RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health
Care (AJF), University of Oxford, Oxford; and the Department of Cardiovas- ...
Cited by 134 - Related articles - BL Direct - All 12 versions

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting …

- sld.cu [PDF] 
CO Phillips, A Kashani, DK Ko, G Francis, … - Archives of internal medicine, 2007 - archinte.highwire.org
Methods MEDLINE (January 1966–December 2006) and Web sites for the National
Institute of Health Clinical Trials and the Food and Drug Administration were
searched for eligible RCTs that included 500 or more subjects, had a ...
Cited by 73 - Related articles - BL Direct - All 7 versions

Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral …

- Free from Publisher
J Rosenstock, AJ Ahmann, G Colon, J Scism- … - Diabetes Care, 2008 - Am Diabetes Assoc
RESULTS—Baseline A1C was similar (PPT 8.8%; BBT 8.9%; P = 0.598). At week 24,
A1C was lower with BBT (6.78 vs. 6.95%, P = 0.021). A1C was reduced
significantly from baseline for both therapies (P < 0.0001). The difference ...
Cited by 29 - Related articles - BL Direct - All 5 versions

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate …


RB Goldberg, VA Fonseca, KE Truitt, MR … - Archives of internal medicine, 2008 - archinte.highwire.org
Methods A prospective, 16-week, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study conducted at 50 sites in the United
States and 1 site in Mexico between August 12, 2004, and December 28, 2005. ...
Cited by 18 - Related articles - All 5 versions

Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care …


LB Haas - Journal of the American Medical Directors Association, 2007 - Elsevier
Approximately 25% of patients in nursing homes have diabetes, and it is the
primary reason for 12% of nursing home admissions among residents 45 to 75 years
of age. Glycemic control is important to reduce the risk of diabetic ...
Cited by 13 - Related articles - All 12 versions

A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin …


A Barnett, J Allsworth, K Jameson, R Mann - Current Medical Research and Opinion®, 2007 - informahealthcare.com
0300-7995 doi:10.1185/030079907X199691 All rights reserved: reproduction in
whole or part not permitted ... CurrEnT MEdiCAl rEsEArCh And OPiniOn® Vol. 23,
No. 7, 2007, 1493–1507 © 2007 liBrAPhArM liMiTEd
Cited by 13 - Related articles - BL Direct - All 5 versions

Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from …

- clinicaltherapeutics.com [PDF] 
A Vinik - Clinical therapeutics, 2007 - Elsevier
Methods: Relevant English-language articles published from 1996 to 2006 were
identified through searches of the National Center for Biotechnology PubMed
database. Search terms included insulin, insulin therapy, type 2 diabetes, ...
Cited by 13 - Related articles - All 4 versions

Rosiglitazone: a review of its use in type 2 diabetes mellitus

- adisonline.com [PDF] 
ED Deeks, SJ Keam - Drugs, 2007 - ingentaconnect.com
0012-6667/07/0018-2747/$49.95/0 © 2007 Adis Data Information BV. All rights
reserved. ... A Review of its Use in Type 2 Diabetes Mellitus ... Emma D.
Deeks and Susan J. Keam ... Various sections of the manuscript reviewed ...
Cited by 10 - Related articles - BL Direct - All 5 versions

Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic …


LR Reynolds, FJ Kingsley, DG Karounos, LR … - Diabetes research and clinical practice, 2007 - Elsevier
Forty subjects with type 2 diabetes and inadequate glycemic control on
sulfonylurea and metformin therapy received 24 weeks of add-on therapy with
either RSG 4 mg daily or IG 10 units daily. Subjects on RSG with fasting ...
Cited by 10 - Related articles - All 10 versions

Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 …

- Free from Publisher
C Triplitt, L Glass, Y Miyazaki, E Wajcberg, A … - Diabetes care, 2006 - Am Diabetes Assoc
RESULTS—A1C and FPG decreased similarly in the glargine insulin (9.1 ± 0.4 to
7.6 ± 0.3% and 212 ± 14 to 139 ± 5 mg/dl, respectively, both P < 0.0001) and
rosiglitazone (9.4 ± 0.3 to 7.6 ± 0.4% and 223 ± 14 to 160 ± 19 mg/dl, ...
Cited by 9 - Related articles - BL Direct - All 6 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google